Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for EYPT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 75.10M
March 31, 2026 59.05M
December 31, 2025 -74.67M
September 30, 2025 55.38M
June 30, 2025 48.34M
March 31, 2025 39.52M
December 31, 2024 -95.96M
September 30, 2024 16.20M
June 30, 2024 -160.40M
March 31, 2024 20.81M
December 31, 2023 -47.15M
September 30, 2023 -1.72M
June 30, 2023 13.47M
March 31, 2023 32.09M
December 31, 2022 32.92M
September 30, 2022 6.272M
June 30, 2022 -0.012M
March 31, 2022 -56.44M
December 31, 2021 -32.96M
September 30, 2021 -0.131M
June 30, 2021 -0.025M
March 31, 2021 0.00
December 31, 2020 -0.192M
September 30, 2020 -0.128M
June 30, 2020 -0.026M
Date Value
March 31, 2020 -0.016M
December 31, 2019 -0.006M
September 30, 2019 0.00
June 30, 2019 -0.025M
March 31, 2019 -0.182M
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
June 30, 2017 2.374M
March 31, 2017 3.335M
December 31, 2016 2.388M
September 30, 2016 5.48M
June 30, 2016 -5.321M
March 31, 2016 1.433M
December 31, 2015 -0.028M
September 30, 2015 -0.546M
June 30, 2015 -0.885M
March 31, 2015 -2.783M
December 31, 2014 -3.058M
September 30, 2014 -0.007M
June 30, 2014 -0.421M
March 31, 2014 -2.264M
December 31, 2013 1.309M
September 30, 2013 1.442M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Ocular Therapeutix, Inc. -3.367M
Eli Lilly & Co. -15.40B
Elanco Animal Health, Inc. -110.00M
Amylyx Pharmaceuticals, Inc. -149.80M
Nuvation Bio, Inc. 5.991M